Stocksigma LogoStocksigma Logo

USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI

Jubilant Pharmova announced that the USFDA concluded its review of the Establishment Inspection Report for the inspection conducted between 8th Jun'26 and

USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI

Jubilant Pharmova Ltd 路 Others (Uncategorized) 路 12 Sept 2026, 1:12 am

USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI Jubilant Pharmova announced that the USFDA concluded its review of the Establishment Inspection Report for the inspection conducted between 8th Jun'26 and 17th Jun'26 at Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA. The regulator classified the sterile injectable and ophthalmic manufacturing site as Voluntary Action Indicated (VAI), successfully concluding the regulatory inspection review without major compliance hurdles.

Original exchange filing (PDF)

More announcements from Jubilant Pharmova Ltd

All Jubilant Pharmova Ltd announcements